Market Overview

FBR Capital Initiates TherapeuticsMD At Outperform, Shares Jump

Share:
Related
15 Biggest Mid-Day Gainers For Friday
Benzinga's Top Upgrades, Downgrades For July 21, 2017

FBR Capital Markets initiated coverage on shares of TherapeuticsMD (NYSE: TXMD) with an “outperform” rating.

The target price for TherapeuticsMD is set to $34.

TherapeuticsMD shares have jumped 54.10% over the past 52 weeks, while the S&P 500 index has gained 19.69% in the same period.

TherapeuticsMD's shares jumped 32.93% to $5.49 in pre-market trading.

Latest Ratings for TXMD

DateFirmActionFromTo
Jul 2017Deutsche BankInitiates Coverage OnBuy
Jul 2017OppenheimerUpgradesPerformOutperform
May 2017OppenheimerDowngradesOutperformPerform

View More Analyst Ratings for TXMD
View the Latest Analyst Ratings

Posted-In: FBR Capital MarketsInitiation Analyst Ratings

 

Related Articles (TXMD)

View Comments and Join the Discussion!